The Benefit of Combining Docetaxel with Androgen Deprivation Therapy in Localized and Metastatic Hormone-sensitive Prostate Cancer is Predicted by ERG Expression: An Analysis of Two GETUG Phase 3 Trials.
Rajpar S, Ibrahim T, Carmel A, Merabet Z, Vielh P, Foulon S, Lesaunier F, Delva R, Rolland F, Priou F, Ferrero JM, Houédé N, Mourey L, Théodore C, Krakowski I, Faivre L, Habibian M, Culine S, Gravis G, Chauchereau A, Fizazi K.
Rajpar S, et al.
Eur Urol Oncol. 2024 Jul 20:S2588-9311(24)00173-1. doi: 10.1016/j.euo.2024.06.015. Online ahead of print.
Eur Urol Oncol. 2024.
PMID: 39034169